Strategic value Position Real Endpoints as a specialist in determining payer value and facilitating coverage and pricing strategies with outcomes-based contracts. Emphasize opportunity to reduce time-to-reimbursement for biopharma and diagnostics partners by leveraging RE Assist and proprietary analytics to demonstrate clinical and economic value.

Payer-Ready solutions Highlight the end-to-end offerings that translate product value into payer coverage, including practical evidence strategies and innovative contracting. Target pharmaceutical firms seeking to optimize access and affordability through risk-sharing arrangements.

Growth leadership Capitalize on recent leadership appointments and awards to establish credibility with potential clients. Use Michael Sherman’s payer insights and the Fierce Healthcare Innovation recognition to open conversations with mid-to-large biopharma and diagnostics companies aiming to scale market access efforts.

Tech-enabled access Leverage RE Assist and its AI crawler with human curation as a key differentiator for clients needing scalable, data-driven patient assistance and access programs. Market to payers and manufacturers facing complex affordability hurdles and SDOH-linked access challenges.

Financial health fit Target companies in the $10M–$25M revenue band seeking specialized market-access partnerships to accelerate reimbursement and sustain cash flow. Real Endpoints’ lean team and specialized services can complement larger sales teams by offering niche, high-impact access solutions.